Reduced nitric oxide bioavailability in a baboon model of Shiga toxin mediated hemolytic uremic syndrome (HUS)

Renal Failure

Volumn 27, Issue 5, 2005, Pages 635-641

  Siegler, Richard L ^a   Pysher, Theodore J ^a   Tesh, Vernon L ^b   Noris, Marina ^c   Cassis, Paola ^c   Taylor Jr , Fletcher B ^d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Hemolytic uremic syndrome (HUS); Nitric oxide (NO); Shiga toxin

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEMOGLOBIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SHIGA TOXIN;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG BIOAVAILABILITY; ESCHERICHIA COLI; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFECTION COMPLICATION; KIDNEY METABOLISM; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASODILATATION;

ANIMALS; BLOOD CHEMICAL ANALYSIS; DISEASE MODELS, ANIMAL; HEMOLYTIC-UREMIC SYNDROME; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PAPIO; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SHIGA TOXIN; URINALYSIS;

EID: 24044546137     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220500200841     Document Type: Article

References (37)

1. Siegler, R.L. The hemolytic uremic syndrome. Pediatr. Clin. North. Am. 1995, 42 (6), 1505-1529.
2. Radomski, M.W.; Palmer, R.M.J.; Moncada, S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem. Biophys. Res. Commun. 1987, 148, 1482-1489.
3. Ikeda, M.; Ikeda, U.; Takahashi, M.; Shimada, K.; Minota, S.; Kano, S. Nitric oxide inhibits intracellular adhesion molecule-1 expression in rat mesangial cells. J. Am. Soc. Nephrol. 1996, 7, 2213-2218.
4. Deng, A.; Baylis, C. Locally produced EDRF controls preglomerular resistance and ultrafiltration coefficient. Am. J. Physiol. 1993, 264 (Renal Fluid Electrolyte Physiol. 33), F212-F215.
5. Argyle, J.C.; Hogg, R.J.; Pysher, T.J.; Silva, F.G.; Siegler, R.L. A clinicopathological study of 24 children with hemolytic uremic syndrome. A report of the Southwest Pediatric Nephrology Study Group. Pediatr. Nephrol. 1990, 4, 52-58.
6. Bohle, A.; Grabensee, B.; Fischer, R.; Berg, E.; Klust, H. On four cases of hemolytic-uremic syndrome without microangiopathy. Clin. Nephrol. 1985, 24 (2), 88-92.
7. Levy, M.; Gagnadoux, M.F.; Habib, R. Pathology of hemolytic-uremic syndrome in children. In Hemostatis, Prostaglandins, and Renal Disease; Remuzzi, G., Mecca, G., de Gaetano, G., Eds.; Raven Press: New York, 1980; 383-397.
8. Dran, G.I.; Fernandez, G.C.; Rubel, C.J.; et al. Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome. Kidney Int. 2002, 62 (4), 1338-1348.
9. Jaradat, Z.W.; Marquardt, R.R. L-arginine as a therapeutic approach for the verotoxigenic Escherichia coli-induced hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Med. Hypotheses 1997, 49 (3), 277-280.
10. Kajiume, T.; Nagita, A.; Yoshimi, S.; Kobayashi, K.; Kataoka, N. A case of hemolytic uremic syndrome improved with nitric oxide. Bone Marrow Transplant. 2000, 25 (1), 109-110.
11. Taylor, F.B., Jr.; Tesh, V.L.; DeBault, L.; et al. Characterization of the baboon responses to Shiga-like toxin (descriptive study of a new primate model of toxic responses to Stx-1). Am. J. Pathol. 1999, 154 (4), 1285-1299.
12. Siegler, R.L.; Pysher, T.J.; Tesh, V.L.; Taylor, F.B., Jr. Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2001, 12 (7), 1458-1467.
13. Thorup, C.; Persson, A.E.G. Macula densa derived nitric oxide in regulation of glomerular capillary pressure. Kidney Int. 1996, 49, 430-436.
14. Pfeilschifter, J.; Kunz, D.; Muhl, H. Nitric oxide: an inflammatory mediator of glomerular mesangial cells. Nephron. 1993, 64, 518-525.
15. McLay, J.S.; Chatterjee, P.; Nicolson, A.G. Nitric oxide production by human proximal tubular cells: a novel immunomodulatory mechanism? Kidney Int. 1994, 46, 1043-1049.
16. Walter, R.; Schaffner, A.; Schoedon, G. Differential regulation of constitutive and inducible nitric oxide production by inflammatory stimuli in murine endothelial cells. Biochem. Biophys. Res. Commun. 1994, 202 (1), 450-455.
17. Koide, M.; Kawahara, Y.; Tsuda, T.; Yokoyama, M. Cytokine-induced expression of an inducible type of nitric oxide synthase gene in cultured vascular smooth muscle cells. FEBS Lett. 1993, 318 (3), 213-217.
18. Breen, D.; Bihari, D. Acute renal failure as a part of multiple organ failure: the slippery slope of critical illness. Kidney Int. Suppl. 1998, 66, S25-S33.
19. Waldman, S.A.; Murad, F. Cyclic GMP synthesis and function. Pharmacol. Rev. 1987, 39 (3), 163-196.
20. Williams, J.M.; Lote, C.J.; Thewles, A.; et al. Role of nitric oxide in a toxin-induced model of haemolytic ureamic syndrome. Pediatr. Nephrol. 2000, 14, 1066-1070.
21. Matsunaga, T.; Nakajima, T.; Sonoda, M.; et al. Reactive oxygen species as a risk factor in verotoxin-1-exposed rats. Biochem. Biophys. Res. Commun. 1999, 260 (3), 813-819.
22. Te Loo, M.; van Hinsbergh, V.; van der Velden, T.; Monnens, L.; van den Heuvel, L. Effects of Verocytotoxin-1 on Nitric Oxide Production by Human Glomerular Microvascular Endothelial and Mesangial Cells, 4th International Symposium and Workshop on "Shiga Toxin (Verocytotoxin)-Producing Escherichia Coli Infections," Kyoto, Japan, 2000.
23. Bitzan, M.M.; Wang, Y.; Lin, J.; Marsden, P.A. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J. Clin. Invest. 1998, 101 (2), 372-382.
24. Siegler, R.L.; Christofferson, R.D.; Edwin, S.S.; Mitchell, M.D. Urinary cyclic GMP as a measure of endothelin derived relaxation factor (EDRF) in the hemolytic uremic syndrome. [abstract]. JASN. 1991, 2, 274.
25. Dedeoglu, I.O.; Feld, L.G. Nitric oxide in the urine of a patient with hemolytic uremic syndrome, [letter]. Pediatr. Nephrol. 1996, 10 (6), 812-813.
26. Gibson, Q.H.; Roughton, F.J.W. The kinetics and equilibria of the reactions of nitric oxide with sheep haemoglobin. J. Physiol. 1957, 136, 507-526.
27. Evans, H.G.; Ryley, H.C.; Hallett, I.; Lewis, M.J. Human red blood cells inhibit endothelium-derived relaxing factor (EDRF) activity. Eur. J. Pharmacol. 1989, 163 (2-3), 361-364.
28. Martin, W.; Villani, G.M.; Jothianandan, D.; Furchgott, R.F. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J. Pharmacol. Exp. Ther. 1985, 232 (3), 708-716.
29. Edwards, D.H.; Griffith, T.M.; Ryley, H.C.; Henderson, A.H. Haptoglobin-haemoglobin complex in human plasma inhibits endothelium dependent relaxation: evidence that endothelium derived relaxing factor acts as a local autocoid. Cardiovas. Res. 1986, 20, 549-556.
30. Rioux, F.; Petitclerc, E.; Audet, R.; Drapeau, G.; Fielding, R.M.; Marceau, F. Recombinant human hemoglobin inhibits both constitutive and cytokine-induced nitric oxide-mediated relaxation of rabbit isolated aortic rings. J. Cardiovasc. Pharmacol. 1994, 24 (2), 229-237.
31. Katusic, Z.S.; Lee, H.C.; Clambey, E.T. Crosslinked hemoglobin inhibits endothelium-dependent relaxations in isolated canine arteries. Gen. Pharmacol. 1996, 27 (2), 239-244.
32. Katusic, Z.S.; Marshall, J.J.; Kontos, H.A.; Vanhoutte, P.M. Similar responsiveness of smooth muscle of the canine basilar artery to EDRF and nitric oxide. Am. J. Physiol. 1989, 257 (4 Pt 2), H1235-H1239.
33. Chou, S.Y.; Ahmed, A.; Porush, J.G. Renal vasoconstriction by endothelin (ET) is augmented by intravascular hemolysis and reversed by calcium antagonists. [abstract]. J. Am. Soc. Nephrol. 1990, 1, 411.
34. White, D.G.M.J.; Sumner, M.J.; Watts, I.S. The effect of endothelins on nitric oxide and prostacyclin production from human umbilical vein, porcine aorta and bovine carotid artery endothelial cells in culture. Br. J. Pharmacol. 1993, 109, 1128-1132.
35. Balla, G.; Vercellotti, G.M.; Muller-Eberhard, U.; Eaton, J.; Jacob, H.S. Exposure of endothelial cells to free herne potentiates damage mediated by granulocytes and toxic oxygen species. Lab. Invest. 1991, 64 (5), 648-655.
36. Motterlini, R.; Macdonald, V.W. Cell-free hemoglobin potentiates acetylcholine-induced coronary vasoconstriction in rabbit hearts. J. Appl. Physiol. 1993, 75 (5), 2224-2233.
37. Siegler, R.L.; Christofferson, R.D.; Cook, J.B.; Edwin, S.S.; Mitchell, M.D. Urinary Cyclic GMP (cGMP) as a Measure of Nitric Oxide (NO) and A trial Natriuretic Peptide (ANP) Activity in Post-Diarrheal HUS, 2nd International Symposium and Workshop on "Verocytotoxin (Shiga-like toxin)-producing Escherichia coli infections," Bergamo, Italy, 1994.